Celebrating the Opening of the Michael G. Harris Cell Therapy and Cell Engineering Facility
Description
Refreshments will be served at 1:45 pm.
Audience
This program is for the research community.
Agenda
SESSION I: STEM CELL THERAPY, 2:00 pm - 3:30 pm
Cell Therapy for Parkinson’s Disease
Lorenz Studer, MD
Director, Center for Stem Cell Biology
Developmental Biology Program, MSK
Clinical Cord Blood Transplantation: Current State of the Art
Juliet N. Barker, MBBS
Director, Cord Blood Transplantation Program
Department of Medicine, MSK
Pluripotent-independent Reprogramming of Endothelial to Hematopoietic Cells by Vascular Induction
Shahin Rafii, MD
Director, Ansary Center for Stem Cell Therapeutics
Weill Cornell Medical College
Globin Gene Transfer for Thalassemia and Sickle Cell Disease
Farid Boulad, MD
Medical Director, Pediatric Day Hospital
Department of Pediatrics, MSK
SESSION II: T CELL THERAPY, 3:30 pm - 5:30 pm
CAR T Cells
The Many Roles of the Cell Therapy and Cell Engineering Facility
Isabelle Rivière, PhD
Director, Cell Therapy and Cell Engineering Facility
Molecular Pharmacology & Chemistry Program, MSK
CD19 CAR T Cell Therapy
Renier Brentjens, MD, PhD
Director, Cellular Therapeutics Center
Department of Medicine, MSK
Mesothelin CAR T Cell Therapy
Prasad S. Adusumilli, MD, FACS
Deputy Chief, Thoracic Service
Department of Surgery, MSK
Enhancing the IQ of CAR T Cells Using the Synthetic Biology Tool Box
Michael Jensen, MD
Director, Ben Towne Center for Childhood Cancer Research, Seattle Children’s Hospital
University of Washington
The Design of Receptors and Cell Products for Cancer Immunotherapy
Stanley Riddell, MD
Member, Fred Hutchinson Cancer Research Center
University of Washington School of Medicine
TCR T Cells
Engineering T Cells to Target Oncogenic Proteins: It Starts with the TCR
Philip Greenberg, MD
Head, Immunology Program, Fred Hutchinson Cancer Research Center
University of Washington School of Medicine
Adoptive Immunotherapy with Transplant Donor or Third Party-derived EBV-specific T-cells for EBV-associated Malignancies
Richard O’Reilly, MD
Chair, Department of Pediatrics
Chief, Pediatric Bone Marrow Transplant Service, MSK
CLOSING REMARKS
Michel Sadelain, MD, PhD
Director, Center for Cell Engineering
Immunology Program, MSK